[18-F] Florbetaben..........T228
[18-F] Fluortriopride..........M254
[18F]ASEM..........M7
[18F]-FEPPA..........32.2
1H-MRS..........60.3, M165
22Q11..........19.4
22q..........11.2 CNVT196, T203
5C-CPT..........T198
5CSRTT..........M146
5-Ht1B..........W65
5-Ht2A Receptor..........W27, W244
5HT2A receptors..........T170, W46
7-DHC..........W51
ABCD..........28.3
Abstinence..........14, M229, M245, W229
Abuse..........W234
Abuse Liability..........M220
Abuse Potential..........T166
Acculturation Stress..........W276
Accumbens..........14.2
Acetylcholine..........9.1, T217, W45
Acetylcholinesterase Inhibitors..........W47
Acoustic Startle Response..........T215
Actigraphy..........2.1, 21.4
Action-Outcome Associations..........W178
Acute Effects..........M252
Acute Stress..........9.3, 30.4, 53, M105, T5, T7, T15, W21, W120, W121, W130, W144, W272
Adaptive Deep Brain Stimulation..........18.3
Addiction..........12, 12.2, 20.2, 20.4, M140, M272, T49, T238, T240, T244, T264, T279, W225, W231, W249, W260, W262, W267, W280
Addiction Circuitry..........M236, M263, W278
Add-On Treatment..........44.1
Adenosine A2A Receptor..........M66
Adiponectin..........16.4
Adolescence..........6, 6.2, 6.3, 6.4, 11, 11.1, 23.1, 28.2, 28.3, 29.3, 40.1, 40.2, 40.3, 40.4, 48.1, 48.3, M33, M34, M35, M38, M48, M61, M227, M230, M267, T20, T81, T93, W35, W38, W40, W58
Adolescent..........27.2, 28, T86
Adolescent Academic Performance..........W271
Adolescent Alcohol..........M233, W247
Adolescent Anxiety..........M26, M36, M143
Adolescent Binge Drinking..........T48
Adolescent Brain and Cognitive Development..........6.4
Adolescent Brain and Cognitive Development Study..........28.1, 28.3
Adolescent Depression..........11.2, M36, M37, M40, M106, T88, T137, W33, W90, W123, W147
Adolescent Development..........6.1, 23.3, 48.4, M168, T43
Adolescent Stress..........M268
Adolescents..........5.2, 40, M49, T95
Adult Hippocampal Neurogenesis..........M40, M116, M120, T174
Adult Onset..........T204
Advance Care Planning..........T168
Adverse Childhood Experiences..........T13
Adversity..........29, 29.3
Advocacy..........62
Aerobic Exercise..........M267
Affect of Adverse Events on Efficacy..........M210
Affect of Adverse Events on Functioning..........M210
Affective Components of Pain..........43, 43.1
Affective Disorders..........M102
Age of Onset..........M188
Aggression..........38, 38.1, 38.2, 38.3, 38.4, M67, M153, M218, M246, T19, W66
Aging..........M4, M7, T1, T26, T56, T57, T176, W2, W110
Aging and Dementia..........M50, M53, T59
Agonist Maintenance..........35.3
Alcohol..........50.3, 54.1, M3, M246, M260, M268, T20, T55, T259, T277, T278, W248, W271
Alcohol and Substance Use Disorders..........50.4, M241, M264, M271, T242, T258, W238, W243, W244, W245, W249, W272
Alcohol Consumption..........59, T232, T262
Alcohol Dependence..........54, 54.2, 54.3, M255, T52, T243, W237, W267
Alcohol Drinking..........59.3, T255, T269, W248
Alcohol Intake..........12.3, 59.2
Alcohol Self-Administration..........59.4, M233, T249, W245
Alcohol Sensitivity..........T232, T280
Alcohol Use Disorder..........59.3, M212, M230, T47, T249, T251, T266, T270, W242, W245, W260, W280
Alcohol Withdrawal..........M269, T265, W253
Alcoholism..........59.1, M143, M144, M244, T254, T275, T281, W280
Alcohol-Seeking Behavior..........M66, T247
ALKS 5461..........W119
Allopregnanolone..........M34
Allostatic Load..........46
Allosteric Modulator..........T257
Alpha Oscillation..........36.1, M47, W126
Alpha-7 Nicotinic Acetylcholine Receptor..........M7, T19
ALS..........T160
Alternative Splicing..........59.1, T36
Alzheimer's Disease..........46.2, M51, M54, T16, W1, W49, W165
AMPA..........M76, M128, W219
AMPA Glutamate Receptors..........T101
AMPA Receptors..........37.3, W91, W219
AMPA TARP Gamma..........8W91
Amphetamine..........T18, T237, W29, W206
Amygdala..........29.1, 53.1, 53.4, 55.3, M10, M13, M65, M114, M134, T15, T22, T48, T72, T82, T125, T150, T194, T277, W7, W39, W52, W74, W96, W114, W123, W171, W235
Amygdala-Hippocampal Differences..........M172
Amyloid..........M5, W48
Analgesia..........M232, T124, W281
Anandamide..........41.1, 41.3, T5
Anatomical Connectivity..........W32
Anesthesia..........T144
Angiogenesis..........M164
Anhedonia..........17.3, M22, M251, T49, T122, W114, W133
Animal Model..........8, 20.3, 29.1, 38, 38.2, 62, M247, T35, T84, T171, T222, T272, W78, W115, W154, W180, W246
Animal Research..........62
ANK3..........T23
Ankryin-G..........M177
Anorexia Nervosa..........T104, W54, W58, W59
Anterior Cingulate..........W203
Anterior Cingulate Cortex..........M146, M278, T93, T248
Anterograde Tracer..........M45
Anthranilic Acid..........T192, W176
Antidepressant..........10.4, 49, 57.2, 57.3, M71, M98, M99, M100, M118, M124, M130, T75, T82, T111, T146, W24, W79, W107, W127, W129, W139, W147
Antidepressant Agents..........W118
Antidepressant Response..........W103
Antidepressant Therapies..........30.4
Antidepressant Treatment Practice..........57.4
Antidepressant Trials..........10.1, W76
Antipsychotic..........52.1, M217, T189, T209, W204
Antipsychotic Induced Weight Gain..........W210, W218
Antipsychotic Medication..........47.4, M54
Antipsychotic Response..........M167
Antipsychotic Treatment..........61.2, M200, T184, T214, W172
Antipsychotic-Associated Obesity..........W30
Antipsychotic-Naïve First-Episode Schizophrenia..........52, 52.2, 52.4, 58.3, M167, T45, T188
Antipsychotic-Naive Schizophrenia..........M179
Antipsychotics..........7.4, M207, M212, T41, T184, W127, W187, W199
Antisocial Personality Disorder..........T180
Anxiety..........4.3, 29.3, 30, 48.1, 55.3, M8, M10, M13, M73, M120, M137, M145, T2, T7, T14, T20, T49, T62, T63, T69, T72, T116, T121, T167, W7, W11, W24, W39, W48, W94, W115, W122
Anxiety Circuitry..........4.2, 30.3, 55.4, M17, M23
Anxiety Disorders..........41.2, T157, W15, W23
Anxious Depression..........T62
APOE..........T228
App..........39
Apparent Diffusion Coefficient..........M156
Appetitive Hormones..........T246
Approach/Avoidance..........M127, M151, W131
Aripiprazole..........M199, W51, W189
Aromatase..........44.2
Artefact Removal..........W256
Arterial Spin Labeling..........M150
Artificial Learning..........W271
Aspirin..........M216, T29
Assessment..........T206
Associative Learning..........W275
ASSR..........W192
Astrocyte..........58.1, M100, W261
Attachment..........29.1, W155
Attention..........M197, T4, T83, T93, T198
Attention Deficit Hyperactivity Disorder (ADHD)..........11.3, M67, M142, M158, T9, T74, T108, W28, W55, W252
Attentional Bias Modification..........M57
Atypical Antipsychotic Drug..........W221
Atypical Antipsychotics..........T206, W212
Auditory..........19.3, T199
Auditory Cortex..........56.1
Auditory Deficits in Schizophrenia..........T205
Auditory Hallucinations..........36.1, T42, T207, W191
Auditory Processing..........T40
Auditory Short-Term Memory..........T205
Augmentation..........51.1
Autism Spectrum Disorder..........1.3, 8, 22.1, 56.4, M39, M47, M92, M147, M148, M150, M158, M164, M204, M213, M215, T76, T83, T85, T86, T90,T92, T173, T203, W32, W37, W41, W42, W43, W180, W143, W150
Autoimmune Encephalitis..........W163
Automated Facial Affect Recognition..........18.3
Autonomic Nervous System..........22.3, W272
Autophagosome..........M203
Autoradiography..........T193
Aversive Conditioning..........T68
Axon Guidance Molecule Genes..........6.1, W149
Axons..........M177
Baby-Cry..........M266
Balb/C Mouse..........W143
Bariatric Surgery..........M56, T164, W61
Basal Ganglia..........M273, T238
Basolateral Amygdala..........M145, M277, T273, W11, W154
Bath Salts..........W230
Bayesian Inference..........12.2
Bayesian Modeling..........M151
BDNF..........38.3, M131, M132, M217, M224, T39, T79, T146, T178, W156
BDNF Delivery..........T97
BDNF Val..........66Met..........W72
Bed Nucleus Of The Stria Terminalis..........30.3, 55.2, 55.4
Behavior..........T30, T92
Behavioral Analysis..........T7
Behavioral Disturbances..........M54
Behavioral Economics..........M89
Behavioral Inhibition..........37, W7
Behavioral Pharmacology..........M247, W236, W251
Benzodiazepine..........M239, W122, W258
Benzodiazepine Diversion..........W258
Benzodiazepine Use Disorder..........W258
Beta-Amyloid Peptide 1-42..........T228
Big Data..........7.2
Binge Eating Disorder..........M57, M62, T103, W55
Bioenergetic..........W213
Bioinformatics..........M99, T117, W215
Biomarker..........1.3, 2, 2.4, 6, 7, 7.3, 7.4, 10, 10.4, 15, 47, 49.2, 52, 52.3, 56.2, 56.4, 57, 58.1, M9, M15, M111, M170, M172, T1, T27, T33, T169, T253, W23, W191, W144
Biotype..........M172, W211
Bipolar..........T221, W211
Bipolar and Unipolar Depression..........T133
Bipolar Depression..........M101, W81, W140
Bipolar Disorder..........5, 5.1, 11.4, 21, 21.1, 33.3, 33.4, 60.1, M4, M70, M78, M81, M92, M102, M115, M119, M123, M190, M206, T23, T24, T25, T29, T78, T108, T112, T118, T119, T123, T135, T140, T150, T153, T202, T219, W78, W85, W96, W110, W111, W112, W227
Bipolar I Depression..........T75
Bipolar I Disorder..........5.3, W190
Blast..........M157
Blood..........52.3
Blood Plasma Analyte..........13.1
Blood Pressure..........M153
Blood-Brain Barrier..........M178, W84
BNST..........55.3, T72
Bodies..........T104
Body Dysmorphic Disorder..........T104
Body Perception..........W226
Body Weight..........W49, W118
Bold Imaging..........T64, T126, T187
Borderline Personality Disorder..........W170
Botox..........W79
Brain..........44.2, W263
Brain Based Markers for Depression..........M126
Brain Connectivity..........49.3, M112, T248
Brain Development..........6.3, 11.4, 23.2, 23.3, 27.1, 28, 28.4, 29, 29.3, 55.3, M22, T91, T105, W39, W66, W243
Brain Glucose Metabolism..........T281
Brain Imaging..........7, 10.2, 33.1, M44, M127, M259, W60
Brain Networks..........7.2, 49.3
Brain Stimulation..........36.1, M59, W37
Brain Stress..........T257
Brain Structure..........T30, T227
Brain Transcription..........10.3, M236
Brain Volume..........M25, M257, T17
Brain Wiring..........T154
Breast Cancer..........W71
Breast Cancer Chemotherapy..........T167
Brexanolone..........W116
Brexpiprazole..........M208, M210, M211
Bulimia Nervosa..........T102, W56
Buprenorphine..........35.1, M77, W94
Buprenorphine-Naloxone..........35.2, 35.3, M225
CACNA1C..........W169
Calcium..........W169
Calcium Imaging..........W65, W75, W155, W262
Calthrin Nanoparticles..........T97
cAMP Signalling..........T146
Cancer..........32, 32.1, W3
Cancer Quality of Care..........T168
Cancer Survival..........T58
Cannabidiol..........M152
Cannabinoids..........T70, T199, W231, W234, W236
Cannabis..........41.1, M201, T236, T268, W246, W264
Cannabis Dependence..........41.4
Cannabis Use..........M141, M219, T43, T55, T274, W265
Cannabis Use Disorder..........41, M226, M282
Cardiac Autonomic Tone..........T73
Cardiolipin..........M115
Cardiometabolic Risk..........W30
Cardiovascular..........M87, M253
Care Coordination..........M225
Cariprazine..........T152, W81, W189
Catecholamine Depletion..........M58
Cats/Foxes..........W166
Caudate..........M161, W34, W203
Causal Modeling..........M21
CB1 Receptor..........M277
CBT..........T3, W17
Celecoxib..........M101, T135, T140
Central Amygdala..........9.2, 14.4, 30.2
Central Autonomic Network..........T73
Central Nucleus of the Amygdala..........55.2, 55.4
Cerebellum..........M264, T34, W150, W194
Cerebral Blood Flow..........M150
Cerebrospinal Fluid..........13, 13.3, 20.1, T96
C-Fos..........W279
C-Fos-Expressing Ensembles..........50.1
Chemogenetics..........30.1, 37.2, M48, W62, W266
Chemokine..........58.3
Child Maltreatment..........M32
Childhood..........T165
Childhood Adversity..........29.4, W177
Childhood Maltreatment..........29.1, T113
Childhood Onset Bipolar Disorder..........T125
Childhood Trauma..........29.4, M37, M42, M46, T28, T207, T274
Childhood Urban-Rural Upbring..........M171, M184
Childhood-Onset Schizophrenia..........M174
Children..........11, 22, T10, T41
Children and Adolescents..........28.1, 28.4, M67, T9, T14, W6, W26, W39
Choice..........T243, T276, W251
Cholesterol Biosynthesis..........T278, W51, W88
Cholinergic Function..........W45
Cholinergic System..........T252
Chorioamnionitis..........22.4
Choroid Plexus..........20.1
Chronic Food Restriction Stress..........W59
Chronic Pain..........25, W227
Chronic Pain Treatment..........25.3, 43, 43.2, T166
Chronic Social Defeat..........M126
Chronic Stress..........17.1, 30.4, 53, M24, M120, T15, T59, T148, T217, T273, W36, W84, W117, W121, W130, W144
Cingulo-Opercular Network..........T13
Circadian Function..........40.3
Circadian Rhythm..........21, 21.4, 40, 40.1, 40.4, M221, T153, T210, T244, W96, W214
Circuit..........6.1, 24.1, 42.1
Circuit Mapping..........M182, M240
Circular RNA..........20, 20.3
Circulating miRNA..........20.1
CLARITY..........W185
Claustrum..........W134
Clinical High Risk..........13, 19.2, T197, W179, W182, W222
Clinical High Risk for Psychosis..........M165, M201
Clinical Outcome Prediction..........33.4
Clinical Trial..........2.4, 44, M79, M149, M175, M212, M255, T6, T40, T41, T159, T269
Clinical Trial Rating Methods..........W139
Clinician Reported Outcomes..........W76
Clozapine..........M183, W221
Clustering..........49.3, M243, T89, W260
CNS Antibody Delivery..........T96
CNS Clinical Trials..........M51, T103
CNTNAP2..........W42
Co-Abuse..........M260
Cocaine..........37, 50.3, M270, T51, T53, T229, T230, T231, T261, T271, T279, T282, W261, W273, W279
Cocaine Addiction..........20.3, 37.2, 37.3, 50.2, M63, M247, M251, M253, M254, T248, T250, W229, W269
Cocaine Seeking..........14, M229, M238, M277, W268, W274
Cocaine Self-Administration..........M236, M237, M267, T273, W240
Cognition..........2.4, 6, 19, 24.2, 24.4, 32.1, 32.3, 36.2, 42.2, 46.2, M79, M159, M168, M169, M206, T34, T39, T57, T163, T167, T191, T213, T223, T227, T256, W50, W121, W141, W145, W182, W188, W202, W209, W220, W264
Cognitive Aging..........M5
Cognitive Behavioral Therapy..........M161, T87, T143, T218, W26
Cognitive Control..........M117, M186, M192, M227, M245, T13, T83, T105, T106, T118, W201
Cognitive Control Network..........T86
Cognitive Decline..........M206, W3
Cognitive Deficits..........22.4, 52.2
Cognitive Enhancement..........31.1, M6, T182, W145, W184
Cognitive Flexibility..........59.4, W8
Cognitive Function..........T272, W49
Cognitive Functioning..........31, M274, T182, W172
Cognitive Impairments..........36, M195
Cognitive Neuroscience..........M40, M68
Cognitive Phenotypes..........26, T37, W74
Cognitive Reappraisal..........W138, W170
Cognitive Remediation..........M218, W173
Cognitive Symptoms..........M170
Cognitive Training..........24.2, 36.3
Cognitive/Emotional Task Performance..........M117, W13
Colony Stimulating Factor-1..........T148
Combat Veteran..........51.4, T64
Comparative Neuropsychopharmacology..........M274
Comparative Studies..........M181
Compulsive Behavior..........12.3, W18
Compulsive Models of Drug Use..........T255
Compulsivity..........T242, T243
Computational Modeling..........12, M245, T106, W63, W131
Computational Psychiatry..........33.1, 57.4, M259, T14, T63, W133, W137
Computerized Cognitive Training..........T40
Concussion..........T64
Conditioning..........M273
Connectivity..........7.2, 27, M9, M19, M94, M124, T104, T130
Connectome..........23, W17
Consciousness..........3.3
Contingency Management..........14.4
Controlled Substance Scheduling..........T166
Correlates..........61.1
Correlation Network..........13.1
Cortex..........M201, W134
Cortical Circuit Function..........M182, M186, M204
Cortical Excitability..........T176
Cortical Excitation-Inhibition Balance..........19.2, M72, T23
Cortical Inhibition..........M72
Cortical Neurons..........M194
Cortical Plasticity..........60.1
Cortical Regulation..........37.2
Cortical Thickness..........T163, T188, W205
Cortical Thinning..........13.2
Corticolimbic..........M45
Corticosteroids..........22.1, W161
Corticosterone..........T226, W143
Cortico-Striatal Circuit..........W63
Corticostriatal Connectivity..........27.3, T154, W149
Corticostriatal Networks..........T107
Corticotropin-Releasing Factor (CRF)..........9, 9.1, 9.2, M142, M246, T66, T257
Corticotropin-Releasing Hormone (CRH)..........9.3, W114
Cortisol..........22.3, 51.4, M21, M38, T132, W59, W100, W120
CPP..........M248
Craving..........12.2, 12.4, M263, T251
C-Reactive Protein..........M93
Creativity..........M119
CRF-R1..........9.2, M8
CRISPR/Cas..........945, M92, W86
Cross Generational Transmission..........W265
CRP..........M3
CSF Biomarkers..........T96, T177, W41
Cue Reactivity..........50, 50.3, 50.4, M223, M238, M263, W67
Cue Reinstatement..........M261, W278
Cue-Induced Craving..........50.2, M263, W246
Cuprizone Short-Term Exposure..........W217
Cyclic AMP..........T175
Cytochrome P450s..........M69, W127
Cytokine..........8, 22, 54.3, M93, M129, M164, M204, M213, M215, M257, T84, T149, W84, W128
Cytoskeleton..........M203
D1 Dopamine Receptors..........31, 31.1, 31.2, 31.3, T34, T234, W162, W193, W194
D2 Dopamine and 5HT2A Serotonin Antagonists..........W46
D2 Receptor..........M207, T53, W5, W134
dACC..........33.1, M26, T107
Dasotraline..........T103
Data Fusion..........W256
Data Quality..........M175
D-Cycloserine..........T87, W9, W26
De Novo Mutation..........T76
Decision-Making..........31, M65, M89, M151, M259, T276, W235
Deep Brain Stimulation..........18.2, 18.3, M110, T128, W8
Default Brain Network..........38.4
Default Mode Network (DMN)..........12.4, 17.4, M56, M256, T89, T179
Deficit Syndrome..........T195
Delay Discounting..........M272, W62
Delirium..........W44
Delta..........9-Tetrahydrocannabinol..........T43
deltaFosB..........M107
Dementia..........T160, T170, W47, W45, W48
Dementia-Related Psychosis..........W46
Dendrites..........T142
Dendritic Remodeling..........T217
Dendritic Spine..........M236, T93, T183, W207
Dentate Gyrus..........M84, T19, T174, W10
Depression..........2.2, 2.3, 10.1, 10.3, 17.4, 24, 33.1, 33.2, 40.2, 43.1, 48.1, 53.3, 57, 57.4, M22, M53, M71, M73, M75, M76, M80, M83, M89, M94, M107, M109, M115, M118, M120, M122, M127, M128, M129, M130, M132, T11, T116, T21, T27, T28, T30, T151, T69, T77, T80, T114, T120, T121, T126, T127, T130, T134, T136, T138, T167, T266, W4, W22, W38, W75, W78, W82, W94, W98, W104, W108, W112, W113, W115, W122, W126, W133, W135, W139, W142
Depression Inflammation Cytokine..........M114
Depression Risk..........W86
Depression Subtypes..........49.4, M125, W89
Depression Treatment Response..........10, M86, T129
Depressive Symptoms..........M93
Desensitization..........W193, W233
Design..........23
Desvenlafaxine..........M82
Development..........23.1, 28.3, M190, T12
Developmental..........22
Developmental Neuroscience..........T90, W188
Developmental Psychopathology..........23.3, 27.1, 28, 29, M143, T250
Developmental Trajectories..........6.2, 11.2
Dextromethorphan/Quinidine..........M274
DHCR7..........W51
Diagnosis..........T75, W163
Diet Induced Obesity..........32, T98, T99, W118
Dietary Supplement..........W228
Dieting..........M60
Diffusion MRI..........T37, T154
Diffusion Tensor Imaging (DTI)..........32.1, M45, M155, M165, T66, T88, T94, W4, W17, W32, W33, W136, W202
Diffusion Weighted Imaging..........7.1, M198
Digital Assessment..........T122
Digital Health Feedback System..........57.4
Dimensional..........M133
Dimensions of Psychosis..........T207
Dimethyltryptamine..........M2
Disorders of Glutamate..........16, W200
Disparities..........T168
Dissociation..........W140
DLPFC..........M80
DNA Methylation..........1.3, M16, M29, M32, M122, T183, T271, W110, W144
Dog..........M162
Dopamine..........6.3, 9.1, 42, 61.4, M30, M135, M183, M201, M205, M207, M212, M234, M241, M250, M268, M279, T2, T32, T184, T200, T235, T264, T267, W43, W66, W151, W160, W184, W214, W223, W232, W240
Dopamine (D2, D3) Receptors..........T114, T201, T239, T245, W69, W189
Dopamine 2 Receptor..........T18, T210
Dopamine 3 Receptor Imaging..........T239, W109
Dopamine Agonists..........M83
Dopamine D3 Receptors..........M239, M254
Dopamine Receptors..........M273
Dopamine Release..........W109
Dopamine System..........M91
Dopamine Transporter..........M270, W58, W225, W242
Dopamine-Deficient Mice..........W214
Dopaminergic Modulation..........T241
Dopaminergic System..........31.4, 33.2, T109
Dorsal Striatum..........16.2, M66
Dorsolateral Prefrontal Cortex..........31.2, M171, M216, W201
Dose-Response Analyses..........2, 2.3, M276
Downregulation..........50.4
DREADD Receptor..........W240
DREADDs..........42.3, T178, W69
Drebrin..........W250
Drug Abuse..........T264, W251
Drug Addiction..........20, 37, 50, 50.1, 53.2, T43, T229, T276, W273
Drug Cues..........T276
Drug Development..........M207
Drug Discovery..........M207
Drug Discovery - New Approaches..........25.1, T175
Drug Discovery/Development..........W193
Drug Liking..........T166
Drug Mixtures..........W234
Drug Relapse..........T261, W168
Drug Side Effects..........W221
Drug Use..........M219
D-Serine..........W165, W175
DSM-5..........T208
Duration of Untreated Psychosis..........27.3, 61.1, 61.2, 61.3, 61.4
Dynamical System..........13.1
Dynorphin..........M240, T142, T277
Dysphoria..........M25
E/I Imbalance..........17.3
Early Auditory Information Processing..........T199
Early Detection..........47, W44
Early Identification of Risk..........M37, T225, W33
Early Intervention..........47, 61
Early Life Stress..........1.2, 29.2, 46.1, T11, T38, T138, W27, W159
Early Psychosis..........27.3, M189, T208
Early Rearing..........55
Eating..........M59, M125
Eating Disorders..........M58, M61, T100, W54, W55, W57, W58
Ecological Momentary Assessment..........M4, M81
Education..........39
EEG Biomarkers..........10.1, 56.4, 57.1, M26, M47, M72, M104, M163, T110, W126, W174
EEG/ERP Electrophysiology..........15, 19.2, 56.3, 60.2, 60.4, M47, M117, T181, T192, T205, T216, T275
Effective Connectivity..........W59
Efficacy and Safety..........41.4
Effort-Cost Benefit Task..........33.1, T187, W108
Eicosanoids..........W90
Electric Field Modeling..........T145, T151
Electroconvulsive Therapy (ECT)..........7.4, M98, M103, T114, T130, T144, T151, W100, W102, W142
Electroencephalography (EEG)..........10, 24.1, 50.2, 56.2, T85, W44, W190
Electron Microscopy..........W277
Electronic Cigarette (E-Cigarette)..........T81
Electrophysiology..........3.2, 3.4, 37.3, 56, M142, M240, M258, M271, T2, T12, T139, T152, T211, T273, W86, W268
Emotion..........M81
Emotion Cognition Integration..........T118
Emotion Modulation..........4, T4
Emotion Processing..........M86, T275
Emotion Recognition..........W222
Emotion Regulation..........49.4, 50.2, M218, T100, T118, W20, W40
Emotional Memory..........W153
Emotional Pain..........43.1
Emotional Processing..........T71, W103
Emotional Regulation..........29.2, T9, T21, T30
Emotional Stress..........9, T84
Endocannabinoid..........16.2, 41.1, 41.2, 41.3, M8, M145, M275, M282, T68, T98, T99, W196
Endogenous Opioids..........W124
Endophenotype..........M174, M214, T213
Engram..........53, 53.4
Environmental Enrichment..........M229
Epidemiology..........T153, W146
Epigenetic..........1.2, 1.3, 46, M16, M152
Epigenetic Regulation..........T277
Epigenetics..........1, 6.1, 10, 10.3, 20.4, 46.1, M18, M32, M69, M269, T26, T38, T48, T60, T183, T230, T231, T278, W27, W144, W196, W265
Epilepsy..........42.1, M152
ERK..........W167
ERP..........19.3, T199
Error Processing..........M11
Errors..........W203
Escitalopram..........M82, M88
Esketamine..........W76, W93, W104, W107
Estradiol..........44.3, W72, W98
Estrogen..........44.1, 44.2, W247
Estrogen Synthesis..........44
Ethanol..........54.1, M230, W263
Ethical Issues..........45
Ethics..........45.1, 45.3
Event-Related Potential..........19.3, 60, T42, T220, W183
Excessive Sleepiness..........M222
Excitabilty..........9, M177
Excitation-Inhibition Balance..........T142
Excitatory Synapses..........W274
Executive Function..........29.4, M5, M50, T17, T57
Executive Network..........61.3
Exosome..........20.1
Expectation Bias..........M265
Experience Dependent Plasticity..........W40
Experimental Design..........M265
Experimental Medicine..........T187
Experimental Therapeutics..........T171
Exploration..........T69
Exposure Therapy..........4.4, T3, T8
Exposure-Response Model..........T263
Expression Quantitative Trait Loci..........T280
Extended Amygdala..........55.1
Extended Release Formulations..........35, 35.1
Extended Reward Network..........37.4
Extended Social-Affective Default Network..........W38
Extended-Release Depot..........T209
Extended-Release Naltrexone..........35.2
Externalizing Disorders..........29.4
Extinction..........4, T53
Extinction Learning..........W268
Eye-Tracking..........T85
F-18 PET Imaging..........31.3
FAAH..........41, T5
Face Emotion Processing..........M182, T65
Factor Analysis..........W249, W267
Familial Risk..........T24, T37
Familiality..........M174
Fast-Acting Antidepressant..........17, 17.2, 46.1, M131
Fatty Acid Amide Hydrolase..........41.1, 41.3
Fatty Acid Amide Hydrolase Inhibitor..........41.4
Fatty Acids..........W90
Fear..........4, M134, T194, W39
Fear Conditioning..........4.2, 53, 53.3, 53.4, T71, W7, W10
Fear Extinction..........4.1, 4.4, 41, 41.3, M12, T70, T178, W9, W10
Fear Generalization..........M23, W12
Fear Memory..........M13, M145, W7
Fear of Flying..........T8
FEAST..........W142
Feature Combination..........7.3
Feature Selection..........T271
Feeding..........30.2
Feeding Behavior..........M55
Female..........38.1, W122, W135
Fetal Brain Development..........W52
Fetal Neurobehavior..........W50
Fine Mapping..........W239
First Episode Psychosis..........61, 61.2, 61.4, M189, T197, W183, W195
First Episode Schizophrenia..........42.3, 52.1, 61.3, W204
FKBP5..........T38
Fluorodeoxyglucose..........M157, M179
fMR1 KO Rat..........W192
fMRI Biomarkers..........10.2
fMRI Faces Paradigm..........M114
fMRI Functional Connectivity..........12.1, 55.2, M49, M96, M133, M139
fMRI/Imaging Genetics..........M85
FMRP..........M194
fMRS..........T186
Focal Electrically Administered Seizure Therapy..........W142
Folate..........W205
Forced Swim Test..........W119
Forebrain..........55.1
Fractional Anisotropy..........M165
Fragile X..........T219
Fragile X Syndrome..........56, 56.1, 56.2, 56.4, W167, W192
Frontal Cortical..........M159, T188
Frontostriatal..........T137
Frustration Tolerance..........T9
Frustrative Non-Reward..........W136
Functional Capacity..........T182, W172
Functional Connectivity..........4.3, 25.4, 47.4, 55, M223, T196, W21, W38, W166, W229, W260
Functional Genomics..........T203
Functional Impairment..........5.1, M54, M109
Functional Magnetic Resonance Imaging (fMRI)..........4.3, 5, 5.3, 7, 10, 10.2, 12.1, 17, 24.1, 24.4, 29.3, 33.1, 33.3, 36.2, 49.1, 49.4, 60.3, M6, M11, M26, M44, M58, M83, M125, M127, M134, M139, M141, M151, M171, M173, M180, M197, M227, M252, M259, M266, M272, M276, T4, T14, T21, T50, T82, T86, T102, T105, T118, T120, T143, T147, T150, T179, T194, T216, T238, T240, T259, T276, W19, W35, W54, W56, W60, W61, W63, W74, W103, W111, W131, W170, W191, W200, W201, W226, W233
Functional Neuroimaging..........3.4, 5.3, 7.1, 12, 49, M46, T233, T254, W13, W37, W98
Functional Organization..........16.1
Functional Outcomes..........T221
Functional Selectivity..........W193
Functioning..........M211
GABA..........17.3, 17.4, M12, M62, M148, T59, T142, W248
GABA MRS..........W35
GABA Neuron..........T252
GABA Transmission..........M49, T52, T176, T243
GABAA..........W167
GABA-A Receptors..........9.2, M108, T141, T258, W116
GABAergic Cells..........W34
GABAergic Circuitry..........33.2, 40.3, T23
GABAergic Interneurons..........19, 19.4, 25.3
GABRA2..........T251, T265
GAD65 mRNA..........M62
GAD67 mRNA..........M62
Galantamine..........W141
Galantamine-Memantine Combination..........W220
Gambling..........W69
Gamma Oscillation..........40.3, 56.1, T212
GCF21..........M162
Gender Differences..........T161, T239
Gender Dysphoria..........W226
Gender Identity..........W226
Gene Co-Expression..........M193
Gene Editing..........45.3
Gene Expression..........1.1, 54.3, 59, 59.2, M13, M111, M136, M251, T60, T279, W208
Gene Manipulation..........45.1
Gene Regulation..........T38, W82
Gene X Environment Interaction..........M190
Gene-Environment Interaction..........1.4, M171
Genetic Architecture..........T67
Genetic Mouse Model..........43.2, T211, W42
Genetic Risk..........M193
Genetic Risk Factor..........6.2, T241
Genetically Modified Model..........45.2
Genetics..........21, 26, M187, T39, T60, T90, T201, T202, W276
Genome Editing..........45.2
Genome-Wide Association Study (GWAS)..........M85, M88, M92, M99, M188, M244, T191, T213, T265, T280, W101, W145, W148, W238, W239
Genomics..........T119, T202
Geriatric..........W4
Geriatric Depression..........W102
Ghrelin..........T259
Global Assessment Of Functioning (GAF)..........M208
Global Changes..........M54
Global Mental Health..........34
Global Outreach..........39
GLT-1..........W254
Glucocorticoid Receptor..........T25, W36
Glucocorticoid Receptor Gene..........M37
Glucocorticoids..........M275, W158
Glu..........N2BW168
Glutamate..........14.3, 16.3, 42, 47.2, 47.4, 52.1, 61.4, M76, M100, M165, T186, T200, W140
Glutamate GABA..........17, 19, 52, 52.2, T47
Glutamate Homeostasis..........16.1, M281, W254
Glutamate Receptor Activity..........T133
Glutamate Transport..........M281
Glutamatergic Synapses..........M185, M194
Glutamine..........M71
Glutathione..........M176
Glycosylation..........T185
Glymhatic Clearance..........M156
GLYX-13..........T79, W75
Goal Maintenance..........M186
Goal-Directed Behaviors..........M66
Golden Hours..........51.2
Gonadal Hormones..........48
GPCR..........25.1, 43, T31, T146
GPS..........T50
Graph Theory..........T143, T238
Gray Matter Volumes..........M42, T207
GT-tg Mouse Model..........T97
Guanfacine..........T54, T182
Gut Microbiome..........M138, M237, W112
Gut Microbiota..........W71
Gut-Brain Axis..........T99, T259, W71
GWAS LOCI..........T35
Habenula..........38.4, M85, T231
Habit..........T250
Habitual Behavior..........59.4
Habituation..........W74, W130
Hallucinogens..........M274
Haloperidol..........W214
HAM-D..........W97
Healthy Individuals..........31.4
Healthy Subjects..........M5, T190
Heart Rate..........M153, W272
Heart Rate Variability..........W259
Hedonic Ingestion..........T164
Hemodynamic Response Function..........M161
Hepatitis C..........M257
Heritability..........T67, W101
Heroin..........M249
Heroin Self-Administration..........W87
Heterogeneity..........W89
High Fat Diet..........32.2, W118
High Risk Psychosis..........11.4, 13.2, 27.1
Higher Level Cognition..........3, 3.2
Hippocampal Subfields..........M27, M103, W161
Hippocampal Volume..........61, 61.2, W161
Hippocampal-Prefrontal..........T178
Hippocampus..........20.2, 44.3, 47, 47.2, 47.3, 47.4, 53.1, 53.2, 53.3, M23, M98, M122, M169, M224, M248, T19, T66, T226, T228, W2, W10, W45, W159, W161, W275, W277
Hippocampus-mPFC Pathway..........19.1
Hispanic/Latinos..........T168
HIV..........32.3, M140, T27, T227, T233, W264
HIV-Associated Neurocognitive Disorder..........32.3, T97, W73
HNK..........W106
Homeostasis..........21, 21.1
Homeostatic..........T219
Homeostatic Plasticity..........14.2, W274
Hormone..........48.3
HPA Axis..........T25
Human Brain Imaging..........31.3, 46.3, M127, M239
Human Clinical Trial..........56.4, M113, T246
Human Connectome..........7, 7.1
Human Genetics..........34, M80, M278, T76, W88, W242
Human Neuroimaging..........4.2, 12.2, 15, 23.2, 24, 24.1, 24.3, 27.1, 33, 37.4, 49.2, M35, M68, M78, M239, M242, T17
Huntington's Disease..........16, 16.2, W70
Hydrocortisone..........51.2, W9
Hydroxynorketamine..........M132, W129, W135
Hyperalgesia..........M160
Hypersexual Disorder..........W225
Hypnosis..........W53
Hypothalamic-Pituitary-Adrenal Axis..........T59, W100
Hypothalamus..........38.1, 38.3
Hypoxia..........M2
IFITM..........M204
Imaging..........61.4, M166
Imaging Genetics..........W186
Immobility..........W143
Immune..........T127
Immune Biomarkers..........58, T84, W50
Immune Markers..........8, M164, M204, M213, M215
Immune Modulation..........M262
Immune System..........M170
Immunohistochemistry..........W185
Impulse Control..........T125
Impulsiveness..........M67
Impulsivity..........M44, M66, M136, M151, M218, M272, T100, T109, T198, T240, W55, W62, W65, W67, W68, W69, W232, W238
Imputation..........T60
In Vivo..........T224
In Vivo Calcium Imaging..........30.3, M120, M126, W11, W12
In Vivo Imaging..........30, 32, W64
Inattentive Symptoms..........W55
Inbred Mouse Strain..........21.4, T61
Incentive Motivation..........M250, M271, W241
Incubation..........14
Incubation of Cocaine Craving..........14.1, 14.2, 14.3
Individual Differences..........12.1
Individual Variability..........T151, T243
Indoleamine 2,3-Dioxygenase..........T135
Infant..........29.1, W50
Infection..........W215
Inferior Frontal Gyrus..........M59
Inflammasome..........M115
Inflammation..........13.2, 22, 22.2, 32, 44.4, 58, 58.2, M3, M71, M90, M93, M101, M112, M129, M166, M189, M237, T26, T46, T94, T140, T55, T135, T167, W71, W90, W215
Inflammatory Cytokines..........22.1, 58.4, T195
Inflammatory Disturbances..........W217
Inflammatory Markers..........16.1, 22.3, 32.3, M213, W172
Infralimbic Cortex..........W268
Inhibitory Control..........M11, M59, W65
Inhibitory Synaptic Transmission..........T141
Innate Alarm System..........W25
Innate Immunity..........M1
Inpatient..........M90
Insight..........W181
Insomnia..........T27
Instrumental Learning..........T262
Insula..........12, 12.1, M94, M125, M240, T4, T233, T255, W52
Insula Connectivity..........12.3, 12.4, 14.4
Insulin Resistance..........46, 46.1, 46.3, T28, T137, T138, W212
Insulin-Like Growth Factor 1..........M31
Integrative Health..........M225
Interim Treatment..........35.3
Interleukin-1..........T52
Interleukin-33..........M137
Internalizing Disorders..........T89
Internet..........57.2
Interneurons..........59.3, M209
Interoception..........T102, T157, T233, W56
Interpersonal Conflict..........T71
Intracranial Self-Stimulation..........T260
Intransal..........M28
Intravenous Administration..........M97
Intravenous Drug Self-Administration..........M280, W230
Intrinsic Excitability..........W274
Intrinsic Period..........40.1
Ion Channels..........W198
Iowa Gambling Task..........M264
Iron..........T253
Irregular Sleep/Wake Rhythm Disorder..........M220, M221
Irritability..........24, 24.3, T9, T14
Ischemia-Reperfusion Injury..........M2
JDTic..........M224
Joint Independent Component Analysis..........T216
JZP-110..........M222
Kalirin..........T222
Kappa Opioid..........W157
Kappa Opioid Receptor..........43.4, M240, M268, T124, T277, W5, W266
Ketamine..........2, 2.1, 2.2, 2.3, 2.4, 16.4, 17.2, 53.3, M28, M77, M87, M95, M96, M97, M100, M106, M107, M116, M121, M130, M132, T79, T111, T144, T162, T205, T212, T247, W20, W89, W92, W103, W106, W107, W122, W135, W140, W151
Kinome Array..........16.3
KO mice..........W281
Kv..........3 Channels..........42, 42.2, 59.3
Kynurenic Acid..........M100, T77, T192, W176
Kynurenine Pathway..........M82, T77, T135, T226, W93, W220
Kynurenines..........M101
Lamotrigine..........T123, W161
Language..........W21
Large Scale Networks..........12.4, M46, T147
Late-Life Depression..........M86, M99, T1, T176, T177
Latency of Acoustic Startle..........W211
Latent Class Analysis..........T165
Lateral Habenula..........W64, W132
Lateral Hypothalamus..........W11
Lateral Orbitofrontal Cortex..........T98, T106
Lateral Septum..........M23
Learning..........W133
Learning and Memory..........T186, W247, 53.2
Learning Health System..........W137
Left-Truncation..........M265
Leukocyte Telomere Length..........W110
Leukocytic miRNA..........13.1
LH..........W106
Life Stress..........T56
Light Therapy..........T6, T134
Limbic Cortex..........M94
Linkage..........W239
Linked ICA..........W256
Lipid Rafts..........T146
Lipids..........T278, W88, W172
Lipopolysaccharide..........M93
Lithium..........M52, T112, T160, W96
Lithium Response..........M123, W111
Local Field Potentials..........M55
Locus Coeruleus..........12.3, M258, T134, T158
Long Noncoding RNA..........20, 20.2, 20.4
Long Term Potentiation..........60, 60.1
Long-Acting Injectable Antipsychotics..........M199, T156, W85
Longitudinal..........57.2, T223
Longitudinal Analysis..........T78, W14
Longitudinal Imaging..........11.1, 11.2, M43, W201
Longitudinal Study..........M22, T39, W183
Long-Term Safety..........T209
Long-Term Treatment..........M95, M208
Long-Term Trial..........T263
Loss..........W123
Low Birth Weight..........M155
LPS..........M77
Lumateperone..........M76
Lurasidone..........T78, W121, W172
Macaque..........29.2, M162
Machine Learning..........5, 5.1, 18.3, 52.4, 57, 57.2, 57.3, M42, M55, M104, T155, T163, T271, W229
Machine Learning Clustering..........T121
MADRS..........M110, T29, W104
Magnetic Resonance Imaging (MRI)..........11.4, 23.1, 27.2, M25, M27, M42, M53, M150, M200, M205, M257, T112, T116, T136, T180, T253, W128, W149, W271
Magnetic Resonance Spectroscopy..........M12, T95, T123
Maintenance Treatment..........M95
Major Depression..........T128
Major Depressive Disorder (MDD)..........2.4, 10.4, 17, 24.4, 33.3, 49.1, 49.2, 49.3, 57.1, M20, M72, M79, M82, M103, M104, M108, M112, M124, M128, M256, T22, T56, T73, T115, T141, T143, T145, T148, T157, T234, W40, W79, W80, W84, W95, W102, W103, W109, W117, W120, W124, W128, W132, W138, W140
Manganese..........T185
Mania..........W78, W125
Marijuana..........M252, M256, M276, M282, T234, T268, W243
Marijuana Policy..........W236
Marmoset..........45.2
Maternal Behavior..........T138, W156
Maternal Depression..........M266, W52
Maternal Immune Activation..........8, M176, M198, T91, T108, W217
Maternal Sensitivity..........T65
Maternal Separation..........M45
MDPV..........W230
Mechanism of Action..........2, M96, M98
Medial Forebrain Bundle..........M110
Medial Prefrontal Cortex..........37.1, M12, M17, M24, M48, M209, T211, T258, W62, W154
Medication..........51.1, W224
Medication Development..........M270
Mediodorsal Thalamus..........3.1, 37.1
Medium Spiny Neuron..........W248, W261
MEF2C..........M194
MEG..........47.1, M191
Memory..........3.3, 4, 47.3, 53, 53.3, 53.4, T15, T132, T175, W2, W208
Memory Consolidation and Extinction..........51
Memory Encoding and Retrieval..........50.1, M141, W12
Memory Loss..........W3
Memory Reconsolidation..........4, 4.1, 4.4, M277, T8
Menopause..........W2, W3
Mental Health Service Use..........57.4
Mentalizing..........W210
Mesolimbic Circuitry..........T139
Mesolimbic Reward Circuitry..........T279
Meta-Analysis..........61.1, M11, M263, T58, T77, W13, W19, W24, W147, W151, W186
Metabolic Function..........W177
Metabolic Safety..........T189
Metabolic Side Effects..........M200, M217, T210
Metabolism..........W263
Metabolites..........T129, T224
Metabolomics..........T119, W92, W212
Metabotropic Glutamate Receptor..........46.1, T237, T249, W253
Meta-Cognition..........W181
Methadone Maintenance Treatment..........W259
Methamphetamine..........14.4, M228, M242, T253
Methionine..........W208
Methohexital..........T144
Methylphenidate..........T63
Mexican Americans..........W276
mGlu..........5M154
mGlu..........R5 Receptors..........M147
Mice..........17.1, T12, T256
Microbiota-Gut-Brain Axis..........W107
Microdialysis..........W108
Microglia..........22.2, 58.1, 58.2, T148, T177, W227
Microglia Dystrophy..........54.1
Microglia Priming..........54.1
Microglial Activation..........M230, W105, W227
MicroRNA (miRNA)..........6.1, 13, 13.1, 13.3, 20, T48
Microtubule..........M203, W207
Migraine..........M160
Mild Cognitive Impairment due to AD..........M50, M52, W184
Mild Traumatic Brain Injury..........51.3, M157
Mindfulness..........M18
Minocycline..........M213
Mismatch Negativity..........19.4, M214, T42
Mitochondria..........T113, T230, W169
Mitochondrial DNA..........W110, W159
Mitochondrial Dysfunction..........W73
Mitochondrial Function..........T204
Mixed Features..........W81
MMN1..........9.3, T199
MMP9..........40.3
Mobile Technology..........T80
Model-Free and Model-Based Learning..........57.2
Moderators..........T87
Molecular Mechanisms..........51, M262, T229
Monetary Incentive Delay Task..........T187
Monoamine Oxidase A..........M29, T180
Monoamines..........T152
Mood..........21.3, 48.3
Mood and Addiction..........W244
Mood Disorder..........11.1, 11.4, 16, 16.4, 33, 40, 46.2, 49, M102, M111, T63, T132, T160, W15
Mood Disorder Subtypes..........M70
Morphine..........M279, T244, W257, W273
Mortality..........M181
Motivation..........30, 30.1, 43.4, T267, W178
Motivational..........T122
Motor Activity..........21.1
Motor Behavior..........W34
Mouse Behavior..........M279
Mouse Model..........22.2, M34, M185, M221, T19, T260, W159
mPFC..........W16, W64
MPTP..........31.1, W162
MR spectroscopy..........M40, W200, W263
MR-PET..........M253
mtDNA..........T204
mTOR..........M132
mTORC1..........M130
Mu Suppression..........W174
Multi-Episode Schizophrenia..........W221
Multi-Modal..........W256
Multimodal Neuoimaging..........52, 52.4, T163
Multi-Site MRI..........W256
Multivariate Connectome-Wide Association Study..........M39
Mu-Opioid Receptor Agonist..........T166
Mu-Opioid Receptors..........25.2, 43.1, M231, W119, W233, W239, W244, W255, W281
Muscarinic Acetylcholine Receptor..........T193, W113
Muscarinic Receptors..........W47
Mutation..........W164
MVPA..........W147
Myelin..........M203, T61
N-Acetylaspartate..........M176, T95
N-Acetyl-Cysteine..........T29
Naltrexone..........35.1, M260, T251, W87
Narcolepsy..........M222
Negative Affect..........43.4, W266
Negative Symptoms..........M188, T190, T195
Neocortical Hyperexcitability..........56, 56.1
Neonatal..........11
Network Analysis..........M124, M197, T143, W19
Networks..........23.1
Neural Activity..........M261
Neural Circuitry..........14, M84
Neural Circuits..........30, 38, 38.1, 43.3
Neural Network Connectivity..........M41
Neural Oscillations..........M186
Neural Plasticity..........60.3, M91
Neural Stem Cell..........M74
Neural-Cardiac Interface..........50.4
Neuregulin-3..........20.2
Neuroactive Steroid..........W116
Neuroanatomy..........W134
Neurobehavioral Disorders..........30.4
Neurobiology..........48.1
Neurocircuitry..........W57, W149
Neurocircuits..........M241, W66, W86
Neurocognition..........52.4, W206
Neurocognitive Functioning..........M174, T165
Neurodegeneration..........M213, W168, W169, W280
Neurodegenerative Disease..........31.1, T155, W164
Neurodevelopment..........1.2, 27, 29.2, M176, W149
Neurodevelopmental Disabilities..........56, 56.3
Neurodevelopmental Disorders..........56.1, M194, W28, W146
Neuroendocrine..........M1
Neuroendocrinology..........51.3, M34, T138
Neurofilament..........M203
Neurogenesis..........M164, W20
Neuroimaging..........5, 7.4, 11, 27.2, 28.2, 50.3, M109, W57, W173
Neuroimmune..........54.3, M230, T52, W280
Neuroimmune Interaction..........M262
Neuroinfection..........T161
Neuroinflammation..........16, 22.4, 32.2, 40.3, 46, 46.2, 54, 54.1, 54.2, 58.1, 58.3, M189, M198, M217, M253, M281, T29, T33, T161, T172, T281, W36, W105, W270
Neuroleptic Malignant Syndrome..........W163
Neurological Disorders..........M102
Neuromarkers of Illness..........7.2
Neuromodulation..........18, 18.2, 33, 33.4, 36, M104, T31, T128, W53
Neuronal Activity..........3, 3.1
Neuronal Biomarkers..........50
Neuronal Culture..........W75
Neuronal Ensemble..........50.1
Neuronal Epigenome..........T91
Neuronal Maturation..........W243
Neuropathic Pain..........25.3
Neurophysiology..........M241, T125
Neuroplasticity..........60, 60.4, M10, M189, T56, T101, W197, W275
Neuropsychiatric..........22.4
Neuropsychiatric Disorders..........6.2, T220
Neuropsychiatry..........M159, W148
Neuropsychology..........M81, M206, T86, W102, W243
Neuroscience Driven Nomenclature..........39
Neurosteroid..........T169
Neurosurgery for Psychiatric Disorders..........18, 18.1
Neurotechnology..........T97
Neurotransmitter Co-Release..........W223
Neurotransmitters..........T235
Neurotrophins..........T140
Neurovascular..........M139, W185
New Drug Development..........W199
Next Generation Sequencing..........M74, M123
NFkB..........M204, W36
Nicotine..........20.2, M234, M260, M280, T81, W141, W203, W232, W264
Nicotine Addiction..........M281, T44, T54, T241, T256, W269
Nicotine Dependence..........12.1, 12.4, 20.1, M33, M243
Nicotinic Acetylcholine Receptors..........M234, M278, T44
NMDA..........M28, M76
NMDA Antagonists..........M96, T162, T198, W168, W200
NMDA Glutamate Receptors..........T282
NMDA Receptor..........14.1, 19.3, 42, 42.1, M185, T199, T211, T212, W99, W163, W165, W175
Nociceptin..........30.2, 30.4, W245
Non-Coding..........M202
Non-Coding RNA..........10.4, 20.3
Non-Human Primate (NHP)..........31.3, 45, 45.2,45.3, M10, M143, M176, T272, W20, W162,W255
Non-Human Primate Model..........45.1, M198, W131, W245
Non-Medical Use..........W258
Non-Pharmacological Therapy..........T62
Nonverbal Reasoning..........M41
Noradrenergic System..........M14
Norepinephrine..........M30, W15
Novel Endpoints..........T269
Novel Targets..........T130
Novel Therapeutics..........M79, T62, T134, T169, T260
Novel Tool..........M67, M248
NTRK3..........M10
Nucleus Accumbens (NAA)..........9.1, M126, M236, M278, M279, T53, T142, T229, T267, T282, W16, W62, W67, W68, W136, W250, W261
Nucleus Accumbens Core..........14.1, T51
Nucleus Accumbens Shell..........M65, T20, T252, W154
Obesity..........46.2, T18, T30, T137, T164, W60, W61
Obsessive-Compulsive and Related Disorders..........M68
Obsessive-Compulsive Disorder (OCD)..........18, 18.1, 18.2, 18.3, M9, M11, M27, M28, M161, T3, T67, T76, T79, T87, T105, W6, W8, W16, W18, W26, W63
Obsessive-Compulsive Symptoms..........T165
Obstetric Complications..........1.4
Occupancy..........W189
Olanzapine..........T214
Olfaction..........M134
Olfactory..........T198
Oligodendrocytes..........T173
Omega-3 Fatty Acid..........T94, T149, T197, W29
One-Carbon Metabolism..........W208
Opiate..........M140, M249, M266, T244, T271, W250
Opioid..........25, M232, M235, M272, W94, W234, W251, W266
Opioid Agonist Treatment..........35, 35.1, 35.4, M232, W228
Opioid Antagonist Treatment..........35, 35.1, M255
Opioid Dependence..........25.2, 35, 35.2, 35.3, 35.4, M259, T263
Opioid Overdose..........W281
Opioid Receptors..........43.3, W80
Opioid Side-Effects..........25.1, 25.2
Opioid System..........25.1
Opioid Withdrawal..........M235
Optochemogenetics..........43
Optogenetics..........12, 19.1, 30, 30.1, 30.3, 53.1, M24, M64, M241, M271, T12, T109, T158, T174, W66, W235
Orbitofrontal Cortex (OFC)..........M109, M261, W136
Orexin..........M247
Orexin Receptor Antagonist..........M220, M221, M247, T158
Oscillation..........19, M191
Oscillatory Activity..........3, 42.1, 57.1
Osteoprotegerin (OPG)..........16.4
Overdose..........W234
Oxidative Stress..........40.3, 46, M73, W121
Oxytocin..........M134, T194, T218, T270, W156, W174, W210, W279
Oxytocin and Addiction..........W278
P2X7..........M113
P300..........W179
PACAP..........W23
Pain..........25.1, 43.3, 43.4, M38, M75, M160, M232, T162, W147, W228, W255
Pain Sensitivity..........T64
Paraventricular Nucleus of the Thalamus..........W130
Parkinsonism..........T170
Parkinson's Disease..........45, T171, T172, W162, W164, W176, W184
Parkinson's Disorder..........T192
Partial Agonist..........T245
Parvalbumin..........40.3, M209
Parvalbumin Interneuron..........17.1, 42.2, T36
Parvalbumin Neurons..........M48, T212, W121
Patch..........W49
Patch Foraging..........T32
Pathalogical Gambling..........T264
Pathophysiology..........47.2
Pathway Analyses..........16.3
Pathways..........21.3
Patient Functioning..........M208
Patient Reported Outcomes..........W76
Pavlovian..........T262
Pavlovian Conditioning..........M242, T101, W15, W231
PDE10A..........W199
Pediatric..........T162, W30
Pediatric PTSD..........M43
Pentosan Polysulfate Sodium..........T46
Perceived Stress..........W259
Perfusion..........23.1, 49.2, M60
Periaqueductal Grey (PAG)..........W25
Perinatal Brain Injury..........22.4
Perinatal Stress..........22, W31
Perineuronal Net..........40.3, T255
Peripartum..........T65
Peripheral Blood Mononuclear Cells..........13
Personal and Social Performance (PSP)..........M208, M211
Personality..........M119, T21
PET Resting Metabolism..........M5
PET Tracer..........31
PharmacoBOLD..........W200
Pharmacogenetic Response..........M167
Pharmacogenetics..........M88, M144, T251, W127
Pharmacogenomics..........W127
Pharmacokinetics..........W113, W269
Pharmacology..........59.2, T90, W57, W204
Pharmacotherapy..........59, M144, M181, M280, T74, T249, T269
Phencyclidine..........W178
Phenotypes..........25.4, M235
Phenotyping..........23, 23.2
Phosphodiesterase 1 Inhibitor..........T172
Phosphodiesterase-4 (PDE4)..........T175
Phosphorus Magnetic Resonance Spectroscopy..........T181
Phosphorylation..........M196
Photometry..........30.1, M250
Physical Exercise..........W45
Placebo Response..........M262
Placenta..........1, 1.1, 1.2, 1.3, 1.4
Plasticity..........M105
Polygenic Risk Score..........1.4, 21.2, M37, M171
Polygenic Scores..........M168
Polymorphism..........W242
Polypharmacy..........T184
Population Genetics..........W148
Population Pharmacokinetics..........M199
Positive Allosteric Modulators..........42.1, M108, T193, W141
Positive and Negative Syndrome Scale..........T206
Positron Emission Tomography (PET)..........58.3, M148, M154, M201, T235, T239, W124, W233, W253, W266
Positron Emission Tomography (PET) Imaging..........42.3, 54, 58.4, 61, M7, M113, M135, M147, M239, M254, T16, T33, T45, T82, T133, T155, T237, T245, W1, W91, W105, W109, W157, W189, W270
Postmortem..........M128, T193, W213, W219
Postmortem Brain Tissue..........52.3, M136, M195, M196, T38, W96, W185, W198
Postmortem Human Brain..........M204, M216
Postpartum Anxiety..........W97
Postpartum Depression..........T2, W97, W116
Posttraumatic Stress Disorder (PTSD)..........4.3, 24, 24.4, 51, 51.1, 51.2, 51.3, 51.4, 53, 53.4, M1, M3, M12, M14, M15, M16, M18, M19, M20, M21, M22, M24, M25, M29, M30, M104, T6, T25, T60, T70, T72, T121, T143, T169, T225, T254, T270, W9, W14, W15, W19, W20, W22, W25, W74, W99, W112, W153
Pragmatic Analysis..........57
Prairie Voles..........M228
Pramipexole..........M83, W109
Prazosin..........M14
Precision Medicine..........18.2, T116
Precision Medicine for Depression..........16.1
Precision Medicine for Mood Disorders..........M113, T147, W137
Precision Psychiatry..........24.2, T121
Preclinical..........54, M220, W257
Prediction..........5.2, 24.4, 57, M21, T80
Prediction Error..........T42
Predictive Model..........5.1, M21, M133
Predictors of Response..........M97, T87
Prefrontal Circuit..........T196
Prefrontal Cortex..........3.1, 6, 14.3, 17.1, 29.4, 37.3, 59.3, M65, M105, M142, M275, T44, T236, W43, W171, W184, W262
Prefrontal-Amygdala-Connectivity..........M43, T12
Pregnancy..........1.1
Prelimbic..........T51, T52
Prematurity..........M155, T17
Premenstrual Dysphoric Disorder..........M74, T131, W72
Pre-Morbid IQ..........M168
Prenatal..........22.1, 22.2
Prenatal SSRI Exposure..........M122, W52
Prenatal Stress..........22.3, M138, W34, W158
Prepulse Inhibition..........T35, T215, W18, W206, W211
Prescription Drug Abuse..........W252
Prescription Opioids..........35.4, W275
Presynaptic Uptake..........W223
Preterm..........M155
Prevention..........51
Prevention of Alzheimer's Disease..........M51, M52
Primate Model..........W41
Probiotics..........W125
Prodrug..........W252
Progesterone..........W98
Prolactin..........M149
Prophylactic..........W92, W135
Prostaglandin..........44.4
Prostaglandin-Endoperoxide Synthase 1..........M216
Protein Interactions..........43.2
Protein Trafficking..........M196
Proteomics..........M196, T31
Proton Magnetic Resonance Spectroscopy..........M148, T47
PSD-95..........M185
P-Selectin..........T46
Psilocybin..........M274
Psychiatric Comorbidity..........T74, W244
Psychiatric Cross Disorder Risk..........W146
Psychiatric Disorders..........48, W92
Psychiatric Genetics..........W117, W225
Psychological Autopsy..........M136
Psychometric Properties..........26
Psychoneuroimmunology..........M262, W31
Psychopharmacology..........W218
Psychophysiology..........T8, W94
Psychosis..........27, 27.2, 28.4, M163, M172, M180, M205, M226, T181, T191, T234, W173, W179, W182
Psychosocial Stress..........25.4, T61, W143
Psychosocial Treatment..........T58
Psychosomatic Medicine..........M102
Psychostimulant..........6.1, T18, T237, W252
Psychotherapy..........51.3, M19
Psychotic Disorders..........T223, W146
Psychotropic Medications..........T204
PTEN..........T173
Puberty..........48, 48.1, 48.2
Punishment..........W262
Pupillometry..........W174
Purkinje Cell..........44.4
Pyramidal Neuron..........19
Quantitative Electroencephalography (qEEG)..........M158, T16
R-(-)-Ketamine..........W129
R-(-)-Norketamine..........W129
Radiotracer..........T239
Rage..........40.3
Randomized..........M79
Randomized Clinical Trial..........35.2, 41.4
Randomized Controlled Trial..........2.3, 44.1
Rapastinel..........M131, T79
Rapid Antidepressant..........M96
Rapid Antidepressant Effects..........M121
Rat..........T268, T272, W29, W87, W257
Rat Models..........M33, M249, T68
Reactive Astrocyte..........W165
Reactive Attachment Disorder..........M32
Real-Time fMRI Neurofeedback..........W171
Reappraisal Training..........W170
Receptor Activator of Nuclear Factor-kB Ligand (RANKL)..........16.4
Receptor Occupancy..........M154
Receptor Trafficking..........W233
Reconsolidation Intervention..........4.1
Recovery..........T150, W85
Refinement..........6.1
Regions of Interest..........M257
Regulatory..........W228
Reinforcement..........T252
Reinforcement Learning..........33.2, M57, W63
Reinforcement-Based Decision-Making..........T106
Reinstatement..........T231, W279
Rejection..........W124
Relapse..........14.4, M275, M281, T115
Relapse and Hospitalization..........W204
Relapse and Treatment Outcome..........M259
Relapse Prevention..........50, M238, W125
Relatives..........M163
Relevance for Outcomes..........61.1, T199
REM Sleep..........W95
Remission..........11.3, W85
Repetitive Behavior..........W160
Repetitive Transcranial Magnetic Stimulation (rTMS)..........M20, M75, M104, T95, T120, T147
Replication..........23
Reproducibility..........23
Research Domain Criteria (RDoc)..........T110, T157, W13, W17, W136
Residency Training..........39
Residual Symptoms..........T115
Resilience..........6.1, W4, W115
Respiration..........T73
Respiratory Depression..........25.2
Response Inhibition..........11.3, 37.4
Resting State..........M19, W260
Resting State Brain Imaging..........M256, W28
Resting State fMRI..........49.3, 61.3, M39, M49, M85, M243, T24, T163
Resting State Functional Connectivity..........6.3, 16.1, 17.4, 28, 28.3, 32.2, 33.4, 38.4, 48.1, 55.4, 59.4, 61, M20, M33, M41, M56, M78, M94, M106, M161, M182, M197, M278, T57, T132, T137, T179, T238, T242, W97, W150
Resting State Intrinsic Connectivity..........11.3, W190
Retina..........21.3, T45, T134, T235
Retrograde Tracing..........55.1
Rett Syndrome..........M31, T173
Reuptake Inhibitor..........M30, T103
Reversal Learning..........T106, W16
Reward..........38.2, 49.1, T10, T81, T101, T190, T240, T267, W98, W231, W241
Reward and Aversion..........T49, T260, W251
Reward Circuitry..........30.4, 40.2, M56, M60, M83, T158, T266, W114
Reward Devaluation..........T51
Reward Network..........T164
Reward Neural Circuitry..........29.3, 32.2, 33.3, 33.4, 48.2
Reward Prediction Error..........33.2, M58, W59
Reward Processing..........24.3, T122, T192, T241
Reward Sensitivity..........W178
Reward-Based Decision-Making..........12.2, 31.4, 33, 37.1, M57, W64, W154
Rhesus..........55.2, T205
Rho Family GTPase..........M131
RiboTag..........T117, W134, W156
Risk..........W14
Risk and Resilience..........M126, W40, W123
Risky Decision-Making..........M231, W232
Rivastigmine..........W49
RNA..........M202
RNA Binding Protein..........20.3
RNA Sequencing (RNA-Seq)..........43, 43.2, 59.1, M164, M193, M229, T11, T61, T117, W72, W156, W198
Rs..........10514299T266
Rumination..........W138
Safety..........W228, W269
Safety Context..........55
Salience Network..........M256, T15
Samidorphan..........T214, W87
SAPAP3..........W16
Scanner Harmonization..........7.2
Schizophrenia..........1.4, 6.1, 7.4, 8, 13, 13.3, 16, 16.3, 19.2, 19.4, 24, 24.2, 36, 36.2, 36.3, 42, 42.2, 44, 44.1, 47, 47.1, 47.3, 47.4, 60.2, 60.3, 61.1, M89, M164, M166, M169, M173, M175, M178, M181, M182, M183, M185, M186, M187, M190, M191, M192, M193, M195, M196, M198, M202, M204, M206, M208, M210, M212, M213, M214, M215, M216, M217, M226, T34, T35, T36, T39, T41, T42, T44, T46, T179, T182, T183, T184, T185, T186, T189, T192, T195, T196, T200, T201, T202, T203, T206, T209, T211, T212, T214, T215, T216, T218, T219, T220, T221, T222, W70, W108, W112, W172, W176, W177, W178, W180, W181, W186, W187, W188, W190, W196, W197, W198, W199, W201, W203, W205, W206, W207, W209, W210, W211, W212, W213, W215, W218, W219, W220, W224
Schizophrenia Databases..........W186
Schizophrenia Genetics..........21.2, T213
Schizophrenia Negative Symptoms..........T187
Schizophrenia Prodrome..........60.4, T208
Schizophrenia Subtypes..........M168, M188, T193
Schizophrenia-Like Behavior..........T43, W70
Schizotypal Personality Disorder..........T179
Schizotypy..........T194, W210
Screening..........W44
Seizure..........T160, W215
Self-Administration..........M228, M249, T259, W246, W268
Self-Other Processing..........T21, W54
Self-Perception..........W226
Self-Referential..........W61
Self-Regulation..........M39, M227, T13, T100
Semantic Priming..........T216
Sensitization..........M246, M279, T237, T264
Sensorimotor Gating..........T215
Sensory Gating..........W192
Sensory-Emotional-Memory..........W61
Serine Racemase..........W165, W175
Serotonin..........M30, M82, W43, W237
Serotonin 1A Receptor..........W120, W166
Serotonin 5-HT2C Receptor..........W67
Serotonin Reuptake Inhibitors..........T131
Serotonin Transporter..........M231, W120
Sex Differences..........1, 1.2, 27.1, 44.2, 44.3, 44.4, 48.2, 48.3, M34, M45, M61, M105, M135, M228, M233, M258, M267, M280, T28, T54, T84, T111, T117, T161, T226, T247, T268, T274, W2, W23, W31, W34, W36, W58, W60, W153, W237, W275
Sex Steroids..........22.1, 48.2, M53, M135, T22
Sexual Dimorphism..........38.1, M63, T124
Short-Term Clinical Studies..........M210
Short-Term Studies..........M211
shRNA..........W114
Side Effects..........T41
Sigma-1 Receptor..........M2
Signal Transduction..........43.2
Sign-Tracking..........W231
Simultaneous PET-MR..........W166
Single-Cell..........W158
SK Calcium-Activated Potassium Channels..........T20
Skin Conductance Responses..........T71
Sleep..........3.4, 21, 40, 40.1, 40.2, 40.4, M156, T228
Sleep Deprivation..........T219, T226, W132
Sleep Disturbance..........T225, T227
Sleep Spindles..........21.2, T16, W195
SLOS..........W51
Slow Waves..........T16, W195
Slow-Wave Sleep..........M44, W95
Smartphone-Based App..........M81, T232
Smoking..........T50
Smoking Status..........W209
snoRNA, miRNA and piRNA..........10.4
SNP..........T215
Social Anxiety..........M35
Social Anxiety Disorder..........T4
Social Behavior..........9.3, M48, M89, M138, M228, T2, T10, W41, W155
Social Cognition..........M197, M218, T194, W54, W181, W210, W222
Social Competence..........48.4
Social Cue Detection..........M173
Social Defeat Stress..........M71, M184, T139, W107
Social Deficits..........M249
Social Discrimination..........T15
Social Functioning..........T218
Social Interaction..........M26, M35, M137, M153, W43
Social Play Behavior..........44.4
Social Preference..........M173
Social Reward..........W38
Social Skills Training..........T218
Social Status..........W157
Social Stimuli..........W174
Social Stress..........M134
Sociality..........M162
Solriamfetol..........M222
Soluble Epoxide Hydrolase..........W90
Somatostatin..........19.3, M23, M209
Sonic Hedgehog Signaling..........W227
Spatial Navigation..........W194
Spiking Neural Models/Rate Models..........3.2
Splice Variants..........25.2
SSRI..........M36, T82, W17, W24
Staging..........5, 5.1, 5.2
STAI..........W97
STAR*D..........W101
Statistical Methods..........W89
Stem Cells..........45, W227
Stimulant..........W252
STN, W8
Stopping..........M64
Stress..........48.1, M73, M130, M162, M275, T26, W92
Stress Cascades..........W217
Stress Induced Depressive Behavior..........M116
Stress Models..........T127
Stress Reactivity..........M80, W237
Stress Resilience..........M116
Stress Response..........M164
Stress-Induced Reinstatement..........T54
Striatal Cortical Circuits..........W28
Striatum..........M142, T31, T101, T107, T233, T256, W5, W133, W160, W241
Structural MRI..........7, 7.1, 11.1, 11.2, 18.1, M32, W1
Structural Neuroimaging..........7.3, M43, T191, W6
Structure of Psychopathology..........6.4
Structure-Activity Relationships..........W230
Subchronic Ketamine Model..........42.3
Subcortical Shape Analysis..........T136
Subgenual..........M109
Subgenual Cingulate Cortex..........T151
Subjective Cognitive Decline..........W48
Subphenotypes..........T202
Substance Abuse..........28, 40, M223, W258, W259
Substance Use..........28.1, 28.2
Substance Use Disorder..........M227, M251, T157, W239
Subthalamic Nucleus..........M64
Subtypes..........57.3, M243, W260
Suicidal Ideation..........2.2
Suicidality..........T95, W93
Suicide..........2.1, 11.1, M85, M90, M97, M111, M187, T25, T130, T149, T208, W82, W88, W124
Suicide Behavior Severity..........M69
Superior Colliculus..........W25
Susceptibility..........W115
Susceptibility Genes..........1
Sustained Attention..........3.2, M146, T217
Sustained Threat of Shock..........55.4
Switch..........W185
Symptom Trajectory..........11.2
Symptom-Onset Treatment..........T131
Synapses..........8, M130, M164, M204, M213, M215, W175
Synaptic Aberrations..........7.4, M185, W70, W207
Synaptic Plasticity..........9, 14, 16.2, 17.2, T53, T98, W99, W130, W175, W261
Synaptic Protein Imaging..........W91
Synaptic Pruning..........T36
Synaptic Vesicle..........W223
Synchronized Transcranial Magnetic Stimulation (sTMS)..........T145
Synchrony..........47.1
Synthetic Opioids..........W281
Systematic Review..........W182
Systemic Inflammation..........M8, M125
Systems Neurobiology..........T196
TAAR 1..........W257
Tardive Dyskinesia..........M149, M183, T159, W152
Target Engagement..........M154
Task-Based Functional Connectivity..........M180
Tau..........T96, W48, W207
TCF4..........T173
Team Building..........34
Technology..........M226, T182
Teenage Onset..........T204
Telomere..........22.3, 46.3, T113
Temperament..........M119
Test Retest..........M180
Testosterone..........48.4
Thalamo-Cortical Interactions..........3, 3.4
Thalamus..........3.2, 3.3, W195
Thalamus - Reticular Nucleus..........3.4
THC..........41, T234, T236, T246
Therapeutic Trial..........T156
Therapeutics..........25, T96
Theta..........19.3, M17
Theta Burst Transcranial Magnetic Stimulation..........W53
Threat..........4.3, 29.3
Threat Context..........55, 55.2
Threat Faces..........24.3
Threat of Shock..........T126
Thyroid Hormone..........M13
Tianeptine..........43.1
Time Estimation..........M276
Timing..........T32, T34, W194
TMEM161B/MEF2C..........T266
TMS Targeting..........M6
TMS-EEG..........M15, W197
TNF-Alpha..........W82
Tobacco..........T50
Tobacco Smoking..........W209, W270
Tolcapone..........M159, M192
Tolerance..........M219
Toll-Like Receptors (TLRs)..........T108
Top-Down Control..........19.4, M146, T93
Touchscreen..........M146, T110, T272
Tract Tracing..........55
Tractography..........18.2, T154
Training..........19.3, 39, T199
Trajectory..........11
Trajectory Modeling..........M21
Transcranial Direct Current Stimulation (TDCS)..........36.2, 36.3, M59, T, W191
Transcranial Magnetic Stimulation (TMS)..........17.4, 24.1, 50.3, M6, M49, M158, M182, M223, T176
Transcription..........T183, W158
Transcription Factors..........W73
Transcriptome..........M70, M244, T230, 279
Transcriptomics..........M31
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS)..........T73
Transdiagnostic..........5.2, 26, M133, M172, M223, W13
Transgenerational..........W31
Transgenic Mice..........30.3, W108
Transgenic Models..........45.2
Transition..........5.2
Translational..........48
Translational Approaches to Drug Development..........56
Translational Biomarker Development..........56.3, T129, W100
Translational Imaging..........32
Translational Medicine..........W199
Translational Models..........T69, W227
Translational Neuroscience..........29, 39, M117, M127, T50, W131
Translational Pharmacology..........M91, W15
Translational Research..........41.2, 54, T13, W31
Translocator Protein (TSPO)..........58, 58.1, 58.2, 58.3, 58.4, M115, W105, W217
Trauma..........M19, M73, T64
Trauma Exposure..........T65, W22
Traumatic Brain Injury (TBI)..........58.4, M159, T169
Treatment..........15, 18, 41.4, 51, W6, W182, W224
Treatment Access..........35
Treatment Adherence..........T156
Treatment Outcome..........52.2
Treatment Outcome Prediction..........49.2, 57.1, W229
Treatment Resistance..........M84, T128, W80
Treatment Resistant Depression..........10.2, M87, M95, M97, M110, M121, T11, T28, T75, W76, W100, W119
Treatment Response..........49.1, M57, M124
Treatment-Resistant Schizophrenia..........52.3
TrkB..........M123
TSPO and [11C]PBR-28 PET..........54.2, W270
Two-Photon..........37.1, M248, T31, T44
Type-2 Diabetes..........M1
Ubiquitination..........52, 52.3
Ultra High-Risk Youth..........W222
Unaffected Relatives..........M174
Vagus Nerve..........T99
Valbenazine..........M149, M183, T159, W152
Validation..........31.3
Valproic Acid..........T92
Varenicline..........M260, M280, W209
Vascular Endothelial Growth Factor..........T140
Vasopressin..........22.2, W41
Vasopressin 1A Receptor Antagonist..........W42
VC/VS..........W8
Venlafaxine..........M99
Ventral Hippocampus..........W11
Ventral Pallidum..........M271, T261
Ventral Striatum..........49.1, M234, T244, W123, W248
Ventral Tegmental Area (VTA)..........30.1, M246, M269, T158, T252, T257, T267, W64, W273
Ventrolateral Prefrontal Cortex..........T150, W205
Ventromedial Prefrontal Cortex..........48.4, W272
Verbal Memory..........M215
Vesicular Glutamate Transporter (VGLUT)..........W68, W223
Veterans..........M118, W153
Virtual Reality..........4.4, M248
Visceral Obesity..........M53
Visual Information Processing..........19.3, M215, T104, T220
Visual Perception..........T188
Visual Plasticity..........60.2, 60.3
Visuospatial Ability..........M41
Visuospatial Working Memory..........M204
VMAT2..........T224, W152
Voxel-Based Morphometry (VBM)..........M63, M156
Vulnerability..........W232, W263
Waitlist..........35.3
Weight Loss Treatment..........M60
White Matter..........11.3, 32.1, M155, W14, W187
White Matter Fractional Anistropy..........M179
White Matter Integrity..........W4, W202
Whole Exome Sequencing..........T76
Whole Genome Sequencing..........26
Whole-Cell Patch Clamp Recording..........W277
Williams Syndrome..........M41
Wistar Kyoto Rat..........M153, W119
Withdrawal..........20
Within Person Variance..........M175
Women..........32.3, M1
Women's Mental Health..........T56, T88, W22
Working Memory..........3.1, 19.1, 31, 31.2, 36.2, 36.3, M6, M209, T59, T236, T268, W194, W202, W205
Working Memory fMRI..........61.3, M184, W138
xCT..........W254
Young Adults..........M78
Youth..........M200
Zebrafish..........T35, T90
Zonulin..........M178
β-arrestin..........W193
Rights and permissions
About this article
Cite this article
ACNP 56th Annual Meeting: Keyword Index. Neuropsychopharmacol. 42 (Suppl 1), S701–S720 (2017). https://doi.org/10.1038/npp.2017.268
Published:
Issue Date:
DOI: https://doi.org/10.1038/npp.2017.268